Holen Sie sich die Stockscreener-App
10.44
3.96%
-0.43
Handel nachbörslich:
10.42
-0.02
-0.19%
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - Investing News Network
MiNK Therapeutics Reports Promising Results from Phase 2 Trial of agenT-797 and N-803 Combination Therapy for Coccidioides immitis Infection - Quiver Quantitative
MiNK Therapeutics Reports New Data on agenT-797, an - GlobeNewswire
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026 - MSN
(INKT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co. - Moomoo
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate - Yahoo Finance
INKT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $35 - GuruFocus
User | bigspringherald.comMiNK Therapeutics, Inc.Common Stock (Nasdaq:INKT) Stock Quote - FinancialContent
About Us - FinancialContent
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics starts phase 2 trial for lung injury therapy - Investing.com UK
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2026 Earnings Conference - Moomoo
Mink Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MiNK Therapeutics (INKT) Q1 2026 loss, cash burn and going concern outlook - Stock Titan
MiNK (INKT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MiNK (INKT) Q1 2026 Earnings Call Transcript - The Globe and Mail
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Acute Lung Injury, Reports Q1 2026 Results and Advances iNKT Cell Therapy Platform - Minichart
MiNK Therapeutics Q1 Earnings Call Highlights - MarketBeat
INKT: Initiated pivotal ARDS trial with strong cash position and expanding clinical data in cancer and lung injury - TradingView
Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress - Investing.com
Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress By Investing.com - Investing.com Canada
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call - Benzinga
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation - Investing News Network
MiNK Therapeutics starts phase 2 trial for lung injury therapy By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MiNK Therapeutics (NASDAQ: INKT) posts Q1 loss and advances Phase 2 lung trial - Stock Titan
MINK THERAPEUTICS ($INKT) Releases Q1 2026 Earnings - Quiver Quantitative
INKT: Advanced iNKT cell therapy into Phase 2 trial, expanded platform, and improved financial position - TradingView
MiNK Therapeutics' Q1 net loss narrows slightly - TradingView
Off-the-shelf cell therapy enters ICU trial for often fatal lung failure - Stock Titan
BRIEF-MiNK Therapeutics Q1 EPS USD -0.57 - TradingView
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - Investing News Network
MiNK Therapeutics and First Lviv Territorial Medical Union initiate randomized phase 2 trial of agent-797 in acute lung injury and critical illness - marketscreener.com
MiNK tests immune cell therapy to help ICU patients breathe - Stock Titan
Mink Therapeutics Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 - Investing News Network
MiNK Therapeutics shows iNKT cell therapy agenT... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
MiNK presents data on iNKT cell therapy agenT-797 at ASGCT By Investing.com - Investing.com South Africa
MiNK presents data on iNKT cell therapy agenT-797 at ASGCT - Investing.com
MiNK Therapeutics Presents Clinical Evidence That a Single, - GlobeNewswire
One off-the-shelf cell triggers tumor attack and calms lung injury - Stock Titan
TradingKey - TradingKey
How MiNK Therapeutics (INKT) earnings power stacks up historically | Q4 2025: Profit SurprisesAnnual Summary - newser.com
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs - The Manila Times
MiNK Therapeutics, Inc. (INKT) plans to release its financial results for the first quarter of 2026 - Bitget
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):